EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study

Sandra Soeria-Atmadja iD, Pauline Amuge iD, Sarah Nanzigu iD, Dickson Bbuye, Jaran Eriksen iD, Johanna Rubin iD, Adeodata Kekitiinwa iD, Celestino Obua iD, Marja-Liisa Dahl iD, Madeleine Pettersson Bergstrand, Anton Pohanka, Lars L Gustafsson iD und 1 weitere

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16272 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Sandra Soeria-Atmadja und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, Intervention and Technology, Division of Paediatrics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Benzoxazines, HIV Infections, Cytochrome P-450 CYP2B6, Anti-HIV Agents. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Swedish Research Council, the Stockholm City Council, the Swedish Order of Freemason Foundation for Children.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Interindividual variations in efavirenz (EFV) plasma concentrations are extensive, but paediatric data on its consequences for viral control are scarce. The aim of this study was to explore the role of genetic variation in achieving therapeutic efavirenz plasma concentrations in a cohort of Ugandan children and the linkage between genetic CYP2B6 variants, EFV plasma variability, viral resistance and viral outcome.

Methods

Ninety‐nine treatment‐naïve children, aged 3–12 years and living with HIV, were followed for 24 weeks after ART initiation assessing mid‐dose efavirenz plasma concentrations, HIV RNA, HIV drug resistance and adherence. Polymorphisms in genes coding for drug‐metabolizing enzymes were genotyped. Efavirenz concentrations were determined by liquid chromatography coupled with high‐resolution tandem mass spectrometry. Metabolizer phenotype was predicted from composite genotypes of CYP2B6 (c.516G>T and c.983 T>C). A mixed effects restricted maximum likelihood regression model was used to identify important factors for efavirenz exposure.

Results

Efavirenz plasma concentrations were below the therapeutic interval (1000–4000 mg/mL) in 12–17% and above in 21–24% of measurements. Eight children had persisting subtherapeutic concentrations, five of which failed virologically and three acquired at least one new resistant mutation. Multivariate modelling explained 70% of interindividual variation in plasma concentration, with treatment duration, adherence, CYP2B6c.136A>G, and metabolizer phenotype as independent predictors of EFV concentration. In univariate analysis, metabolizer phenotype explained 50% of interindividual variation.

Conclusions

Metabolizer phenotype explained 50% of interindividual variation in efavirenz plasma concentration. Autoinduction was not confirmed and >33% of the concentrations were outside the therapeutic interval. Subtherapeutic concentrations worsened virological resistance and outcomes. Genotype‐based dosing may help avert both sub‐ and supratherapeutic efavirenz plasma concentrations in Ugandan children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazinesHIV InfectionsCytochrome P-450 CYP2B6Anti-HIV AgentsHumansCyclopropanesAlkynesChildMaleUgandaChild, PreschoolFemaleProspective StudiesTreatment FailureDrug Resistance, ViralGenotypeReverse Transcriptase InhibitorsViral LoadHIV-1

Stichwörter der Autor:innen

HIV/AIDSantiretroviralschildrencytochrome P450 enzymesgenetic polymorphism

Substanzen

efavirenzBenzoxazinesCyclopropanesAlkynesCytochrome P-450 CYP2B6CYP2B6 protein, humanAnti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Science, Intervention and Technology, Division of Paediatrics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden.
  • Baylor College of Medicine, Children's Foundation-Uganda, Kampala, Uganda.
  • Department of Clinical Pharmacology & Therapeutics, Makerere University, Kampala, Uganda.
  • Unit of Infectious Diseases/Venhälsan, Södersjukhuset, Stockholm, Sweden.
  • Department of Public Health, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Sandra Soeria-Atmadja, Pauline Amuge, Sarah Nanzigu, Jaran Eriksen, Johanna Rubin, Adeodata Kekitiinwa, Celestino Obua, Marja-Liisa Dahl, Lars L Gustafsson, Lars Navér

Förderung

  • the Swedish Research Council
  • the Stockholm City Council
  • the Swedish Order of Freemason Foundation for Children
  • the Samariten Foundation
  • the Jerring Foundation
  • Karolinska Institutet Funds
  • The Center for Innovative Medicine-CIMED at Karolinska Institutet
  • Holmia

Zitieren

APA

Soeria-Atmadja, S., Amuge, P., Nanzigu, S., Bbuye, D., Eriksen, J., Rubin, J., Kekitiinwa, A., Obua, C., Dahl, M. L., Pettersson Bergstrand, M., Pohanka, A., Gustafsson, L. L., & Navér, L. (2025). Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16272

Vancouver

Soeria-Atmadja S, Amuge P, Nanzigu S, Bbuye D, Eriksen J, Rubin J, et al. Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16272

BibTeX
@article{SoeriaAtmadja2025,
  author = {Soeria-Atmadja, Sandra and Amuge, Pauline and Nanzigu, Sarah and Bbuye, Dickson and Eriksen, Jaran and Rubin, Johanna and Kekitiinwa, Adeodata and Obua, Celestino and Dahl, Marja-Liisa and Pettersson Bergstrand, Madeleine and Pohanka, Anton and Gustafsson, Lars L and Navér, Lars},
  title = {Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16272}
}
Kostenlos starten →